^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tavolixizumab (MEDI0562)

    i
    Other names: MEDI0562, MEDI 0562, MEDI-0562
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    5ms
    Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, Providence Health & Services | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    tavolixizumab (MEDI0562)
    3years
    Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors. (PubMed, Clin Cancer Res)
    Following dose escalation, moderate toxicity was observed in both treatment arms, with no clear efficacy signals demonstrated.
    Journal • Combination therapy
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • tavolixizumab (MEDI0562)
    over5years
    Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients With Advanced Solid Tumors. (PubMed, Clin Cancer Res)
    MEDI0562 was safely administered at doses up to 10 mg/kg in heavily pre-treated patients. On-target pharmacodynamic effects were suggested in this setting. Further evaluation with immune checkpoint inhibitors is ongoing.
    Clinical • Journal
    |
    FOXP3 (Forkhead Box P3)
    |
    tavolixizumab (MEDI0562)
    over5years
    [VIRTUAL] Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. (ASCO 2020)
    Background: We report safety and tolerability of MEDI0562, a humanized IgG1κ OX40 monoclonal antibody (mAb), in combination with durvalumab (durva; anti-PD-L1 mAb) or tremelimumab (treme; anti-CTLA-4 mAb) in patients (pts) with previously treated advanced solid tumors. The safety profile of MEDI0562 in combination with durva or treme was similar between groups. Clinical activity was observed with MEDI0562 + durva in pts with advanced solid tumors. Research Funding: AstraZeneca
    Clinical • Combination therapy
    |
    TNFRSF4 (TNF Receptor Superfamily Member 4)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • tavolixizumab (MEDI0562)